HELX
Franklin Genomic Advancements ETF
HELX is an actively managed portfolio of global equity securities of companies relevant to genomic discovery.
Fund Basics
| Fund sponsor | Franklin Templeton |
| Category | Global Equities |
| Asset class | Equity |
| Website | link... |
| Inception date | Feb 25, 2020 |
| Assets (mns) | $9 |
| Expense ratio | 50 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | Annually |
| Taxation | 1099 |
| Stock selection | Proprietary |
| Weighting | Proprietary |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| THERMO FISHER SCIENTIFIC INC | 6.2 % |
| DANAHER CORP | 6.1 % |
| MEDPACE HOLDINGS, INC. | 5.5 % |
| REPLIGEN CORP | 5.2 % |
| VERTEX PHARMACEUTICALS INC | 4.2 % |
| REGENERON PHARMACEUTICALS | 4.1 % |
| SARTORIUS AG PREF | 3.6 % |
| SAMSUNG BIOLOGICS CO., LTD. | 3.0 % |
| KRYSTAL BIOTECH, INC. | 3.0 % |
| CORTEVA INC | 2.8 % |
Constituent Breakdown
| Number of holdings | 56 |
| Herfindahl-Hirschman Index | 295 |
| Wgt avg mkt cap (mns) | $47,144 |
| Large cap (>$10bn) | 65.7% |
| Mid cap ($2-10bn) | 22.5% |
| Small cap (<$2bn) | 5.5% |
| Developed mkts. | 97.0% |
| Emerging mkts. | 3.0% |
Country Exposure
 |
UNITED STATES | 77.3 % |
 |
GERMANY | 7.2 % |
 |
SOUTH KOREA | 3.0 % |
 |
SWITZERLAND | 2.8 % |
 |
BRITAIN | 2.7 % |
 |
NETHERLANDS | 2.0 % |
 |
IRELAND | 1.4 % |
Historical Performance
Standardized Annual Returns (as of 08/31/2023)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | Incep. |
|---|---|---|---|---|---|---|
| 2.2% | -4.1% | -25.9% | -4.5% | -- | -- | 6.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.95 | 44% |
| MSCI EAFE | 0.79 | 32% |
| MSCI Emg Mkts | 0.73 | 26% |
Liquidity Measures
| Avg. volume (000) | 1 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.30% |
| ADV of underlying (mns) | $7,611 |
Technical Indicators
| Recent close | $28.34 |
| 30d moving avg. | $29.95 |
| Annualized volatility | 25.6% |
| Relative strength (RSI) | 33 |
| Short interest (ETF) | 0.0% |
| Short interest (underlying) | 0.0% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HELX |
Expenses vs. HELX |
ALTAR Score™ vs. HELX |
|---|---|---|---|---|
| BBH | VanEck Biotech ETF | 30.7% | -15 bp | +3.4% |
| SYNB | Putnam BioRevolution ETF | 29.4% | +20 bp | +1.5% |
| WDNA | WisdomTree BioRevolution Fund | 27.8% | -5 bp | -6.5% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 27.5% | +6 bp | +0.7% |
| HTEC | ROBO Global Healthcare Technology & Innovation ETF | 27.0% | +18 bp | -1.3% |
| IBB | iShares NASDAQ Biotechnology ETF | 24.0% | -5 bp | -1.2% |
| FXH | First Trust Health Care AlphaDEX Fund | 22.6% | +11 bp | +6.2% |
| GNOM | Global X Genomics & Biotechnology ETF | 21.5% | 0 bp | -8.6% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 21.0% | -31 bp | -0.7% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 20.0% | -10 bp | +6.9% |
Risk and Returns: HELX vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
EPS Revision Activity (6 mo. ago = 100%)
Compound Annual Growth Rates
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| 2022 | 2023E | Fwd Est | 2024E | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 9/28/2023
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
HELX
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Fund Rating
Our measure of an ETF's overall investment merit
ALTAR Score™
HELX
1.9%
Cat. Avg
4.2%
Fund Category: Global Equities
| Avg. Return on Equity | --% |
| Divided by: Fwd. P/BV | --x |
| Less: Expenses | -- bp |
| Equals: ALTAR Score™ | 1.9% |
Recommendation
UNDERWEIGHT
Below average appreciation potential. A rating of UNDERWEIGHT is assigned to ETFs with ALTAR Scores in the 2nd quintile (ranking higher than only 20%-40%) of their category. Typically, funds in this category consist of stocks trading at relatively expensive valuations and/or having below-average fundamentals.
Category Overview
There are 345 funds in the Global Equities category, with an average ALTAR Score™
of 4.2% and a standard deviation of
5.2%. HELX's ALTAR Score™ is approximately
0.5 standard deviations
below
the category average. This places HELX in the 33rd percentile among funds in the category.
Consensus Recommendation
Sell-side recommendations on the ETF's individual constituents
Composite
HELX
Peer Average
Recent Trends
SELL
U/W
HOLD
O/W
BUY
Recent Trends
Breakdown
Market Activity
| Latest price | |
| Change | |
| Volume | |
| Bid/Ask Spread | |
| Update |
Today's Trading
Trading data provided for free by IEX. By accessing this data you agree to abide by their Terms of Service.
Total Cost of Ownership (TCO) Comparison
| Expense (bp) (A) |
Avg. Bid/Ask (bp) (B) |
TCO (bp) (A)+(B) |
|
|---|---|---|---|
| HELX | 50.0 | 29.9 | 79.9 |
| Peer Avg. | -- | -- | -- |
For a detailed cost analysis of this and any other ETF use the TCO Comparison Tool .